Myelofibrosis

A randomized phase 3 study of parsaclisib plus ruxolitinib for adults with myelofibrosis appeared unlikely to meet its primary endpoint and will be discontinued, according to the agents’ manufacturer.

Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, according to study results presented at ASH Annual Meeting and Exhibition.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.

The combination of ruxolitinib and pegylated interferon alpha-2a exhibited encouraging activity among patients with myelofibrosis who had not previously received either drug, according to study results presented at ASH Annual Meeting and Exposition.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), discussed a case study, presented at the 14th International Congress on Myeloproliferative Neoplasms, of dizygotic twins.

Srinivas K. Tantravahi, MBBS, MRCP(UK), spoke with Healio about both nonpharmacologic interventions and pharmacologic developments for patients with myeloproliferative neoplasms.

In this video, Brynn H. Parsegov, PA-C, highlighted two presentations from the 14th International Congress on Myeloproliferative Neoplasms.

Healio spoke with Brynn H. Parsegov, PA-C, about a presentation exploring the timing, as well as impact, of diagnosis for myeloproliferative neoplasms.

In this video, Brynn H. Parsegov, PA-C, discussed a case of fraternal female twins who sequentially presented with JAK2V617F mutation-positive myeloproliferative neoplasms.